Neurocrine Biosciences Board Authorizes $300M Stock Buyback
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has announced a $300 million stock buyback plan, with an accelerated share repurchase transaction to follow, subject to market conditions.
October 30, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences' board has authorized a $300 million stock buyback, with plans for an accelerated share repurchase. This move is likely to positively impact the stock price in the short term.
Stock buybacks generally reduce the number of shares outstanding, potentially increasing the stock price. The accelerated share repurchase indicates a swift execution, which can lead to a quicker positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100